Clinical Trial

Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This NANT trial will determine the maximum tolerated dose (MTD) of autologous expanded natural killer (NK) cells when combined with standard dosing of dinutuximab and will assess the feasibility of adding lenalidomide at the recommended Phase II dose of the expanded NK cells with dinutuximab, for treatment of children with refractory or recurrent neuroblastoma.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2015-10-08; most recent amendment 2026-03-19.
Status change: Recruiting → Active, Not Recruiting 2022-07-28
Status change: Not Yet Recruiting → Recruiting 2018-11-19
Trial Details
NCT Number NCT02573896
Lead Sponsor New Approaches to Neuroblastoma Therapy Consortium
Collaborators: Nationwide Children's Hospital, United Therapeutics
Conditions Neuroblastoma
Enrollment 13 participants
Start Date 2019-01-14
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-23